Voorhees, Peter M.

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

Lonial, S., Weiss, B. M., Usmani, S. Z., Singhal, S., Chari, A., Bahlis, N. J., Belch, A., Krishnan, A., Vescio, R. A., Mateos, M. V., et al. (2016) · The Lancet

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 854

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.

Lonial, S., Lee, H. C., Badros, A., Trudel, S., Nooka, A. K., Chari, A., Abdallah, A.-O., Callander, N., Lendvai, N., Sborov, D., et al. (2020) · The Lancet Oncology

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 812

Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma

Richardson, P. G., Jacobus, S. J., Weller, E. A., Hassoun, H., Lonial, S., Raje, N. S., Medvedova, E., McCarthy, P. L., Libby, E. N., Voorhees, P. M., et al. (2022) · New England Journal of Medicine

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 487

Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma

Usmani, S. Z., Weiss, B. M., Plesner, T., Bahlis, N. J., Belch, A., Lonial, S., Lokhorst, H. M., Voorhees, P. M., Richardson, P. G., Chari, A., et al. (2016) · Blood

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 407

Management of relapsed multiple myeloma: Recommendations of the International Myeloma Working Group

Laubach, J., Garderet, L., Mahindra, A., Gahrton, G., Caers, J., Sezer, O., Voorhees, P., Leleu, X., Johnsen, H. E., Streetly, M., et al. (2016) · Leukemia

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 258

THE PROTEASOME AND PROTEASOME INHIBITORS IN CANCER THERAPY

Voorhees, P. M., & Orlowski, R. Z. (2006) · Annual Review of Pharmacology and Toxicology

Ubiquitin and proteasome pathwaysProtein Degradation and Inhibitors

Cited by 247

Longer term outcomes with single‐agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13‐month follow‐up from the pivotal DREAMM‐2 study

Lonial, S., Lee, H. C., Badros, A., Trudel, S., Nooka, A. K., Chari, A., Abdallah, A., Callander, N., Sborov, D., Suvannasankha, A., et al. (2021) · Cancer

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 144

Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma

Fonseca, R., Usmani, S. Z., Mehra, M., Slavcev, M., He, J., Cote, S., Lam, A., Ukropec, J., Maiese, E. M., Nair, S., et al. (2020) · BMC Cancer

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 127

Daratumumab or active monitoring for high-risk smoldering multiple myeloma

Dimopoulos, M. A., Voorhees, P. M., Schjesvold, F., Cohen, Y. C., Hungria, V., Sandhu, I., Lindsay, J., Baker, R. I., Suzuki, K., Kosugi, H., et al. (2025) · New England Journal of Medicine

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 121

Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)

Landgren, C. O., Chari, A., Cohen, Y. C., Spencer, A., Voorhees, P., Estell, J. A., Sandhu, I., Jenner, M. W., Williams, C., Cavo, M., et al. (2020) · Leukemia

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 102

A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma

Holkova, B., Zingone, A., Kmieciak, M., Bose, P., Badros, A. Z., Voorhees, P. M., Baz, R., Korde, N., Lin, H.-Y., Chen, J.-Q., et al. (2016) · Clinical Cancer Research

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 48

Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma

Richardson, P. G., Durie, B. G., Rosiñol, L., Mateos, M.-V., Dispenzieri, A., Moreau, P., Kumar, S., Raje, N., Munshi, N., Laubach, J. P., et al. (2023) · Haematologica

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 9

A qualitative study of patient and provider perspectives on using web-based pain coping skills training to treat persistent cancer pain

Rini, C., Vu, M. B., Lerner, H., Bloom, C., Carda-Auten, J., Wood, W. A., Basch, E. M., Voorhees, P. M., Reeder-Hayes, K. E., & Keefe, F. J. (2018) · Palliative and Supportive Care

Pain Management and Opioid UseCancer survivorship and care

Cited by 7